30,200 Shares in ESSA Pharma Inc. (NASDAQ:EPIX) Bought by Lepercq Multi Asset Fund

Lepercq Multi Asset Fund purchased a new position in ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,200 shares of the company’s stock, valued at approximately $54,000. ESSA Pharma comprises about 0.0% of Lepercq Multi Asset Fund’s holdings, making the stock its 11th largest holding. Lepercq Multi Asset Fund owned about 0.07% of ESSA Pharma at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BML Capital Management LLC bought a new stake in shares of ESSA Pharma in the fourth quarter worth $7,557,000. Magnus Financial Group LLC bought a new stake in shares of ESSA Pharma in the fourth quarter worth $99,000. FNY Investment Advisers LLC bought a new stake in shares of ESSA Pharma in the fourth quarter worth $44,000. RTW Investments LP increased its stake in shares of ESSA Pharma by 41.9% in the third quarter. RTW Investments LP now owns 3,261,496 shares of the company’s stock worth $19,765,000 after buying an additional 962,834 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in ESSA Pharma by 37.2% during the third quarter. Parkman Healthcare Partners LLC now owns 345,902 shares of the company’s stock valued at $2,096,000 after purchasing an additional 93,830 shares during the last quarter. Institutional investors own 75.12% of the company’s stock.

ESSA Pharma Price Performance

EPIX stock opened at $1.64 on Friday. ESSA Pharma Inc. has a 1-year low of $1.40 and a 1-year high of $9.60. The firm has a fifty day moving average price of $1.73 and a two-hundred day moving average price of $3.25. The firm has a market cap of $72.80 million, a price-to-earnings ratio of -2.38 and a beta of 1.59.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Tuesday, February 11th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). As a group, analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.

ESSA Pharma Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.